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Abstract
The study of metabolomics can provide valuable information about biochemical pathways and processes at the molecular level.
There have been many reports that have examined the structure, identity and concentrations of metabolites in biological systems. However, the binding of metabolites with proteins is also of growing interest. This review examines past reports that have
looked at the binding of various types of metabolites with proteins. An overview of the techniques that have been used to characterize and study metabolite–protein binding is first provided. This is followed by examples of studies that have investigated
the binding of hormones, fatty acids, drugs or other xenobiotics, and their metabolites with transport proteins and receptors.
These examples include reports that have considered the structure of the resulting solute–protein complexes, the nature of the
binding sites, the strength of these interactions, the variations in these interactions with solute structure, and the kinetics of
these reactions. The possible effects of metabolic diseases on these processes, including the impact of alterations in the structure and function of proteins, are also considered.
Keywords: metabolomics, drug–protein interactions, hormone–protein interactions, fatty acid–protein interactions, xenobiotic–protein interactions, protein modification

1. Introduction

tion information and data from complex samples such as tissues
and cells [1, 2].
Research in metabolomics can involve either targeted or untargeted approaches [7]. In a targeted approach, researchers use
techniques such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) for the identification, quantification, and structural characterization of specific metabolites.
This information can be used to examine specific classes of metabolites and to provide information on the biochemical pathways
that are involved in metabolism [2]. In an untargeted approach,
scientists use global profiling to analyze the group of chemicals in
a metabolome as a whole. This second approach is less specific and
sensitive than the targeted approach but allows for the highest
possible coverage of the metabolites that may be involved in biochemical pathways [7].
A significant amount of recent research has been devoted to
metabolic profiling, or the identification and measurement of the
different metabolites that are present and produced in the metabolome [8]. However, it is also important to consider the interactions that occur between metabolites and biological agents, such
as the binding of cofactors to enzymes, hormones to receptors,
and drugs or their metabolites to proteins [8]. Information on
these interactions can be combined with structural data to provide a better understanding of the regulatory networks and connections in biological pathways. Such information, in turn, could
provide a better understanding of how healthy and disease states

Metabolomics is a field that involves the study of low mass compounds (i.e., metabolites) that are produced through metabolic
processes [1, 2]. Metabolites are part of a collection of chemicals known as the “metabolome”, which can include small molecules that are found in cells, tissues, organs, or biological fluids.
The area of metabolomics is of interest because the identity and
concentration of metabolites can provide information about cellular activity and can be directly related to processes such as protein and gene expression [1, 2, 3]. This means that metabolomics
can provide information on the phenotypes of individuals at the
molecular level [3]. In addition, the characterization and examination of metabolites could lead to new discoveries in biomedical research and personalized medicine [1, 3].
Research in metabolomics began in the late 1990s and early
2000s, with the emphasis at that time being on the effects of different metabolites on the gene expression of bacteria and yeast
[1]. The first examples of metabolomic studies utilized two-dimensional thin-layer chromatographic separations to characterize metabolites in samples. This provided researchers with evidence that variation in the concentrations of metabolites can
affect cellular activity [1, 4, 5, 6]. Further progress in the area of
analytical methods such as structural characterization and separation methods has resulted in the development of new instruments and techniques that can be used to provide high resolu1
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differ at the molecular level and could provide vital data that can
be used for pharmaceutical development [7, 9].
This review will look at previous studies that have examined
biological interactions as related to metabolites and proteins as
binding agents. This will include an overview of the various methods and techniques that have been used in this work to study metabolite–protein interactions. A summary will also be provided
of the different types of metabolite–protein binding interactions
that have been investigated with these approaches. In addition,
the possible effects that metabolic diseases may have on these interactions will be considered.
2. Techniques for examining metabolite–protein
interactions
The characterization of metabolite–protein interactions can provide a better understanding in clinical diagnostics of the cellular
activity and the biochemical pathways that are present in various
medical conditions [1–3, 9]. There are many methods that can be
used to examine the binding of metabolites with proteins. These
methods may involve the direct examination of binding that occurs between proteins and low mass drugs, hormones and their
metabolites, or may involve an examination of the free concentrations of these molecules [9–12]. The approaches that are used for
this purpose can be divided into three categories: in vitro, in vivo
and in silico techniques [9, 11–46].
2.1. In vitro methods for studying metabolite–protein
interactions
In vitro methods are the most popular techniques used to characterize metabolite–protein interactions. This approach involves the use
of standard, well-controlled conditions and reagents that are used
in the laboratory to mimic conditions seen in biological systems. To
examine metabolite–protein interactions, in vitro methods may use
a binding assay (e.g., one based on ultrafiltration or equilibrium dialysis) to examine an interaction or to identify the chemicals that
are involved in this process [9]. This approach can provide information such as the strength of the interaction, as well as the thermodynamics and kinetics of binding and possible conformational
changes that occur as a result of the interaction [13–15]. Alternatively, an in vitro study may make use of a method that directly examines the structure of a protein and a bound metabolite, such as
occurs in X-ray crystallography or NMR spectroscopy [1, 16–20].
Other methods may examine the protein–metabolite complex, as
demonstrated with mass spectrometry [24–29].
There are many in vitro approaches that can be used to examine
the binding of proteins with small molecules and their metabolites.
For instance, radiometry and fluorimetry can be used with a binding assay by employing labeled metabolites that contain either a radioisotopic label or fluorophore, respectively [10, 21–23]. These labeled metabolites are then incubated with proteins and the signal
that is produced from the label is measured, such as through a displacement assay or a proteome microarray [10, 23]. Radioisotopic
labeling has been applied to enzymes to determine their activity in
metabolomic reactions [9]. One example involved the screening of
potential inhibitors for an enzyme, in which the substrate was radioactively labeled and the resulting metabolite profiles were analyzed and measured [21]. Fluorescence labeling can provide similar
results to radiolabeling; however, this method can also be used to
identify and determine the location of a binding site for a metabolite on a protein, such as by observing the displacement of specific
probes that are bound to known locations on a protein [10].
Surface plasmon resonance (SPR) and calorimetry are two
other methods that can provide information on the strength of

Figure 1. Crystal structure for the complex of human androgen receptor ligand-binding domain with testosterone (Testo). Reproduced with permission from Reference [30].

protein–metabolite binding and the thermodynamics or kinetics
of this interaction [13–15]. Studies based on SPR utilize an immobilized protein on a sensor chip, in which changes in the resonance energy (e.g., from binding of the protein with a target) are
detected [9]. The change in this signal is related to the mass of the
bound metabolites and can be used to determine the equilibrium
constants for this process or, if examined over time, the association and dissociation kinetics that occur between the metabolite
and protein during binding [9]. The reaction between a metabolite and protein can result in heat being absorbed or given off [9,
13]. Calorimetry can then be used to measure the overall enthalpy
of the binding reaction between a metabolite and a protein [13].
NMR spectroscopy and X-ray crystallography are two tools
that have been used to characterize the structures of metabolite–
protein complexes [9, 16–20]. NMR spectroscopy has often been
used in recent years for characterizing and identifying metabolites in biological samples, but this method can also be used to examine conformational changes that occur during the binding of
metabolites with proteins [18–20]. X-Ray crystallography can also
give structural information on such interactions by providing detailed information on the binding sites and active sites for hormones, drugs and their metabolites or related compounds on proteins and enzymes [16, 17], as is illustrated in Figure 1 [30].
Mass spectrometry can not only be used as a tool for analyzing
the structure and identity of metabolites, but it can be used to analyze metabolite–protein interactions in which information about
enzymatic processes or binding by small molecules is generated
[9]. Experiments utilizing various types of mass spectrometry,
such as quadrupole mass spectrometry or matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry (MALDITOF MS), have allowed for monitoring of the resulting products
and analysis of the reaction kinetics of enzyme-substrate reactions [7, 24, 25]. Further analysis through high resolution mass
spectrometers (e.g., an orbitrap or Fourier transform ion cyclotron resonance mass spectrometry) has resulted in accurate analyses of enzymatic activities in which the intermediate steps in enzymatic reactions can be identified [26–29].
Various separation techniques can also be used to examine
metabolite–protein interactions. Examples of traditional methods that have often been utilized for this purpose are equilibrium
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Capillary electrophoresis (CE) is another separation method
that can be used to examine metabolite–protein binding [9, 37,
40, 41]. One way this method can be used is to separate the free
and bound metabolites through the differences in their size-tocharge ratios. This approach can be utilized alone to determine
the affinity of metabolite–protein binding or combined with other
methods such as mass spectrometry to examine this interaction
[41]. One form of CE is affinity capillary electrophoresis (ACE),
in which a biological molecule such as a protein is used as a running buffer additive, thus making it possible to obtain data on the
interactions of solute components with this additive [40]. Like
HPAC, ACE is a relatively fast method and can be used with small
amounts of sample for the screening or analysis of metabolite–
protein interactions [38, 40].
Figure 2. Example of a competition study using high-performance affinity chromatography to examine the interactions of an injected site-selective probe with a solute that is present at a known concentration in the mobile phase. This example shows the change in the retention factor (k) that
was measured for R-warfarin as a probe for Sudlow site I of human serum
albumin (HSA) in the presence of various concentrations of tolbutamide as
a competing agent. These results were obtained for columns that contained
two clinical samples of HSA that had different levels of modification due to
glycation. Adapted with permission from Reference [39].

dialysis, ultrafiltration, and ultracentrifugation [9, 31–33]. Equilibrium dialysis and ultrafiltration can both be used to separate
protein-bound metabolites from free metabolites through the use
of a semipermeable membrane. These methods are commonly applied to binding studies to determine the affinity of proteins with
drugs and small solutes but can be employed in the same way to
examine the interactions of metabolites with proteins [31]. Ultracentrifugation can be used to provide a similar separation of
free and protein-bound forms of a metabolite by utilizing a gravitational field in combination with a density gradient to separate
these fractions [9, 32]. However, each of these methods does have
limitations, such as difficulty in detecting small free solute fractions, undesirable adsorption of solutes onto the membrane (e.g.,
in ultrafiltration or equilibrium dialysis) or overestimation of the
free fraction due to release of the bound solute during the separation process [33].
Various chromatographic techniques have also been employed
to separate free and protein-bound metabolite fractions [34]. As
an example, size exclusion chromatography (SEC) can be applied
to this type of analysis when metabolite–protein complexes and
free metabolites have a sufficiently large difference in size. In this
type of study, metabolites or small molecules are incubated with a
protein, and SEC can be used to remove the small molecules from
proteins [34]. Such a method can be used for either the isolation
and preparation of metabolite–protein complexes, which can later
be analyzed by other methods, or can be used in binding studies
to provide information on the association equilibrium constant
for a metabolite–protein interaction [8, 34, 35].
Affinity chromatography and high-performance affinity chromatography (HPAC) have also become popular for analyzing solute–protein interactions [35–38]. These affinity methods have an
immobilized biological molecule, such as a protein, as the stationary phase. When used in a low-performance setting, affinity chromatography can be used in a similar way as SEC in that it can be
used for preparation and purification. The use of more rigid and
efficient supports in HPAC allows this approach to be used as a
rapid and relatively high-throughput method for providing information about solute–protein interactions. This information
can include data on the affinity, thermodynamics and kinetics of
these processes, as well as information on the types of sites that
are involved in the interaction (see Figure 2) [35–39].

2.2. In vivo methods for studying metabolite–protein
interactions
Although in vitro methods can provide detailed information about
metabolite–protein interactions, in vivo analysis can provide a
better representation about the metabolite–protein interactions
within a biological sample [8, 9]. This is particularly true in a situation where a protein may undergo post-translational modifications that result in changes in the protein’s interactions with solutes such as drugs and their metabolites [9]. In vivo methods are
often similar to techniques used for in vitro studies but must be
able to work with complex samples. In many cases, clinical samples from patients can be obtained and analyzed through approaches such as labeling, NMR or MS structural characterization,
and affinity separation methods. By utilizing in vivo studies, researchers are better able to understand the effect of disease states
on metabolite–protein interactions, as well as related biochemical
pathways and regulatory processes [9, 39].
2.3. In silico methods for studying metabolite–protein
interactions
Another area of examining metabolite–protein interactions is
through in silico tools [9]. These methods utilize computational
schemes to determine the docking configurations of a metabolite’s
binding sites on proteins or enzymes, as obtained through the use
of molecular modeling or quantum mechanics [42, 43]. This approach can provide information about the structure of a metabolite–protein complex at a given binding site through an analysis of
the most thermodynamically favorable configurations. These computational methods can result in docking predictions that have a
1.5–2 Å accuracy with success rates of 70–80% [43]. If the location
of a binding site is not known in advance, a homology method can
be used to predict binding sites on a protein through the use of the
protein’s amino acid sequence and chemical structures of the metabolites [44]. This method can allow for accurate prediction of ligand-binding proteins and enable the development of a database
for these peptide sequences selected for binding to different metabolites [9, 45]. These in silico methods can be combined with in vitro
analysis to optimize the structural characterization of metabolite–
protein interactions, as demonstrated in NMR experiments [46].
3. Interactions of proteins with hormones and related
metabolites
Hormones are chemicals that are secreted by endocrine glands.
Hormones play a significant role in many regulation pathways,
including metabolism, growth and development [47, 48]. Examples of low mass hormones include various types of steroids (e.g.,
estrogens and testosterone) or thyroid hormones (e.g., thyroxine) [49–52]. As these chemicals enter the circulation, they are
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Table 1. Site-specific association equilibrium constants (Ka) for thyroxine and related compounds with HSA at 37 °C. a

Ka (M−1 × 105) a

		
Compound

R3

R5

R3′

R5′

Thyroxine (T4)
I
I
I
I
					
Triidothyronine (T3)
I
I
I
H
					
Reverse triiodothyronine (rT3)
I
H
I
I
Diiodothyronine (T2)
I
I
H
H
Thyronine (T0)
H
H
H
H

Chiral form
L-T4b
D-T4
L-T3
D-T3
L-rT3
L-T2
L-T0

Sudlow site I

Sudlow site II

1.4 (±0.1)
5.5 (±0.9)
0.170 (±0.001)
1.45 (±0.06)
1.99 (±0.07)
0.63 (±0.03)
0.18 (±0.02)

5.7 (±0.8)
29. (±2)
0.25 (±0.02)
1.2 (±0.2)
3.3 (±0.6)
1.16 (±0.06)
–

a. Each value in parentheses represents a range of ±1 S.D. All association equilibrium constants were measured at 37 °C and pH 7.4. The data shown in this table was obtained from Refs. [53, 54]. Sudlow site I and Sudlow site II are also known as the warfarin site and indole site, respectively.

carried to their target tissue or organ to produce an effect. Many
low mass hormones are transported in the bloodstream through
their binding to serum proteins [51, 52]. These transport proteins
may bind to a broad range of hormones and other targets, as occurs for human serum albumin (HSA), or they may be specific for
a given hormone or group of hormones, as is the case for thyroxine-binding globulin (TBG) [49]. Once it has been delivered to its
target tissue or organ, the hormone can then bind with a receptor
to produce an effect. This section will consider interaction studies that have been reported for several types of hormones or their
metabolites with serum proteins and hormone receptors.
3.1. Thyroid hormones
Thyroid hormones are a group of iodothyronine compounds that
are responsible for metabolism, growth, development, and the
regulation of iodine within the body [47]. Many of these hormones are bound in the bloodstream to both HSA through lowto-moderate affinity interactions and to transthyretin or TBG
through higher affinity processes [48, 49]. An important compound in this group is the hormone l-thyroxine (l-3,5,3′,5′tetraiodothyronine, or T4), which can be metabolized to form
l-3,5,3′-triiodothyronine (T3) [53, 54]. Both T4 and T3 are actively
involved in regulatory processes and are more than 99% bound to
transport proteins in blood [49, 53, 54].
Several studies have explored the structural differences between thyroid hormones and related compounds as they bind to
serum proteins or cell surface receptors [53–55]. One report utilized HPAC to characterize the binding of T4, T3 and related compounds with HSA; the results were used to examine both the
affinity constants and thermodynamic properties of these compounds in their interactions with this protein [54]. Some typical
results that were obtained in competition studies and through the
use of site-specific probes are provided in Table 1. The results indicated that these thyroid hormones were interacting with HSA at
both of the major drug-binding sites on this protein (i.e., Sudlow
sites I and II) [53, 54]. A comparison of the data obtained for the
thyroid hormones and their metabolites indicated that the number and position of iodines, the phenol group, and the thyronine
backbone were all important during the binding of these compounds to HSA [54]. Structural studies have also been carried out
through the use of modeling and crystallographic data to examine
the binding of thyroxine and related compounds to a cell surface
receptor for thyroid hormones on αvβ3 integrin [55].

3.2. Steroid hormones
The protein binding of steroid hormones and their metabolites
has also been characterized through a variety of techniques. As
an example, the crystal structure of the serum transport protein
sex-hormone binding globulin (SHBG) was determined for a complex of this protein with 5α-dihydrotestosterone [56]. SHBG is an
important binding agent in blood for many sex hormones and related compounds, including estradiol, testosterone, androste-5ene-3β,17β-diol, and 5α-dihydrotestosterone [47, 49, 56]. The
information that was obtained from the crystal structure for the
5α-dihydrotestosterone/SHBG complex was compared with the
results of previous binding studies for steroid hormones with
SHBG [57, 58], and this allowed a model of the binding site for
these compounds to be developed. This model gave good agreement with prior data from site-directed mutagenesis [59–61] and
photolabeling experiments [62, 63] that have been conducted
with SHBG [58].
Another structural study looked at the interactions between
the human androgen receptor (AR) ligand-binding domain and
several androgen-related steroid hormones and metabolites [30].
The compounds that were examined included testosterone, dihydrotestosterone, and tetrahydrogestrinone. An example of some
of the results was provided earlier in Figure 1. Both the binding
affinity and structural characteristics for the complexes of these
agents with AR were explored. Tetrahydrogestrinone was found to
have the highest affinity for the AR ligand-binding domain. This
strong binding was thought to be due to the presence of greater
van der Waals interactions for this compound than for the other
steroids that were studied. Dihydrotestosterone had a higher affinity than testosterone, an effect that was proposed to be due to
the stronger electrostatic interactions between the structure of
dihydrotestosterone and the AR binding domain [30].
4. Interactions of proteins with fatty acids and related
metabolites
Fatty acids can also have significant binding to proteins. These
compounds are carboxylic acids that contain hydrocarbon chains
with lengths of 4 to 36 carbons. In some fatty acids, the hydrocarbon chain is unbranched and fully saturated, such as myristic acid (C14:0). In others, the chain contains one or more double
bonds, as is the case for linoleic acid (C18:2) [48]. Long chain fatty
acids (i.e., fatty acids with chains containing 16–20 carbons) are
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stead, the affinity is generally dependent on the hydrophobic portion of the fatty acid and how it interacts with HSA [69]. It has
further been demonstrated that some fatty acids can have direct
competition with drugs on HSA or can lead to allosteric effects
during these binding processes [72, 74, 75, 78].
5. Interactions of proteins with drugs and related
metabolites

Figure 3. Structure of HSA, showing the regions that bind palmitic
acid. This structure was generated using Protein Data Bank (PDB) file
ID: 1E7H [75] and is adapted with permission from Reference [74].

particularly critical for a diverse set of cellular and metabolic functions. For instance, long chain fatty acids act as fuel that can be
stored as triacylglycerols (or triglycerides) and that can be used
to generate ATP through β-oxidation in mitochondria and peroxisomes. In addition, fatty acids are the precursors of phospholipids
and glycolipids, which are needed for the construction of membranes [64].
Long chain fatty acids such as oleic (C18:1), palmitic (C16:0),
linoleic (C18:2), stearic (C18:0), arachidonic (C20:4) and palmitoleic
(C16:1) acid are crucial intermediates in lipid metabolism [65].
They tend to have low solubility in water and are typically bound
in plasma to proteins, with less than 0.1% being present as nonbound, or “free”, fatty acids. Most of the long chain fatty acids in
the blood are transported by HSA [65–68]. HSA carries between
0.1 and 2 mol of fatty acids under normal physiological conditions.
However, this value can rise to as high as 6 mol fatty acid per mol of
HSA in the peripheral vasculature during fasting or exercise or disease states such as diabetes, liver and cardiovascular disease [67].
Many recent studies have attempted to locate fatty acid binding sites on HSA by using X-ray crystallography or NMR spectroscopy [67, 69–73]. Some typical results of such studies are provided in Figure 3 [74, 75]. In addition, site-directed mutagenesis
has been utilized with these methods to see how specific changes
in the peptide sequence of HSA will affect its binding properties and structure [67, 69]. Such studies have revealed that five
to seven binding sites on HSA may be occupied by medium and
long chain fatty acids [71]. These binding sites are asymmetrically
distributed across the three domains of HSA, with three of these
sites overlapping Sudlow sites I and II [70]. All of these sites have
similar structural interactions with fatty acids, providing a deep
hydrophobic pocket for the methylene tail and containing two or
three polar surface residues nearby which provide a binding location for the carboxylic head group of the fatty acid.
A variety of techniques have been employed to estimate the
binding constants for fatty acids at their sites on HSA. The strongest of these interactions have association equilibrium constants
that range from 105 and 108 M−1[66, 74–77]. It has been observed
for fatty acids with multiple binding sites on HSA that the value
of the individual association constants for each mole of added
fatty acid increases as the length of the fatty acid chain was raised
[71]. It was later found that the association equilibrium constant
for the first bound fatty acid increases with chain length but that
this increase does not necessarily occur in a linear fashion; in-

Numerous studies have examined the interactions of drugs and
their metabolites with proteins. Like low mass hormones, many
drugs and their metabolites are transported throughout the body
through the use of serum transport proteins. Approximately 43%
of the 1500 most commonly used pharmaceutics have at least 90%
binding to such binding agents [35, 79]. These interactions usually involve proteins that can bind to a broad range of targets, such
as HSA and alpha1-acid glycoprotein (AGP), and can play a significant role in determining the activity, distribution, rate of excretion
or metabolism, and toxicity of many pharmaceutical agents in the
body [80]. In recent years there has also been interest in how the
presence of drug metabolites can affect the distribution, apparent
activity, and protein interactions of the parent drug [81].
5.1. General effects of metabolites on drug–protein
interactions
Many studies have investigated the difference between drugs and
their metabolites in their overall binding in serum or to specific
serum proteins. For instance, equilibrium dialysis was used to examine the binding of propisomide and its major metabolite to
human serum and isolated serum proteins such as AGP [82] and
the binding of acetohexamide and its metabolite (−)-hydroxyhexamide to HSA [83]. Another study utilized a similar approach to
investigate the binding by tolterodine and its 5-hydroxymethyl or
N-dealkylated metabolites to human serum, HSA and AGP [84].
Equilibrium dialysis was further used to measure the binding of
tizoxanide, an active metabolite of the drug nitazoxanide, with albumin and AGP [85].
A few studies have been conducted to provide a more detailed comparison of the binding regions and binding constants
for drugs and their metabolites on serum proteins. As an example, HPAC and competition studies have been used to compare
the binding regions on HSA for the drug phenytoin and its two
major metabolites: 5-(3-hydroxyphenyl)-5-phenylhydantoin and
5-(4-hydroxyphenyl)-5-phenylhydantoin (i.e., m-HPPH and pHPPH, respectively) [81, 86]. In an examination of both the major and minor drug binding regions of HSA, phenytoin was found
to have direct binding at Sudlow site II and the digitoxin site, with
association equilibrium constants at these regions in the range of
0.65–1.04 × 104 M−1 at 37 °C and pH 7.4 (see Table 2). The same
drug had allosteric effects plus possible direct binding at Sudlow
site I and the tamoxifen site [86]. However, m-HPPH and p-HPPH
only had significant interactions with Sudlow site II, with binding
constants of 0.32–0.57 × 103 M−1 for this region [81]. Thus, the
parent drug and its metabolites not only had different affinities
for HSA but also had differences in the number of their interaction sites with this protein [81, 86].
5.2. Effects of chirality on drug metabolite–protein binding
Another factor to consider for drug- and drug metabolite–protein binding is the effect of chirality on these interactions. Chiral
drugs have been estimated to represent 40–50% of all drugs that
are currently on the market [87, 88]. The separate chiral forms for
some drugs can exhibit a wide variation in their toxicology, pharmacokinetics and metabolism. In the extreme case, one enantio-
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Table 2. Association equilibrium constants (Ka) and types of binding for phenytoin and its metabolites to various regions on HSA. a
Binding region on HSA

Drug or drug metabolite

Phenytoin
m-HPPH
			

p-HPPH

Sudlow site Ib
Sudlow site IIb

No binding
Direct binding
Ka = 5.7 × 103 M−1
No binding

Digitoxin site
Tamoxifen site

Allosteric effects + possible direct binding
No binding
Direct binding
Direct binding
Ka = 1.04 × 103 M−1
Ka = 3.2 × 103 M−1
Direct binding
No binding
Ka = 6.5 × 103 M−1		
Allosteric effects + possible direct binding
No binding

No binding

a. All of these results were obtained at 37 °C in pH 7.4, 0.067 M phosphate buffer and are based on data from References [81, 86].
b. Sudlow sites I and II are also known as the warfarin site and indole site, respectively.

mer may produce the desired function in treatment while another
may be inactive or even produce undesired or toxic effects. This
is because within the body numerous compounds (i.e., enzymes,
plasma proteins, and other biomolecules) work as chiral selectors,
causing them to sometimes bind or metabolize each chiral form of
a drug differently [89–95].

Figure 4. Chiral separation and analysis of tramadol and its major metabolites using HPLC and a column containing immobilized AGP as the
stationary phase. The results in (a) are for a blank human plasma sample. The results in (b) are for a plasma sample taken from a volunteer
2.5 h after receiving a 100 mg dose of racemic tramadol. Symbols: enantiomers of tramadol, +(T) and −(T); enantiomers of the metabolite Odesmethyltramadol, +(M1) and −(M1); enantiomers of the metabolite
N-desmethyltramadol, +(M2) and −(M2); and internal standard (fluconazol), IS. Adapted with permission from Reference [96].

These differences have made it possible in the past to use protein-based HPLC columns, such as those containing serum proteins, for separating the various chiral forms of many drugs [93–
95]. The same approach has been utilized to separate and measure
chiral drugs and their metabolites in biological samples. For instance, an AGP column was recently used with fluorescence detection to measure the enantiomers of tramadol and its two major
metabolites, O-desmethyltramadol and N-desmethyltramadol, in
plasma samples (see Figure 4). This method was then used to examine the pharmacokinetics for each of these compounds in the
body [96]. A similar approach has been used with LC-MS to examine the chiral forms of methadone and its metabolites 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine
and
2-ethyl5-methyl-3,3-diphenyl-1-pyrroline in hair samples from patients
undergoing methadone maintenance therapy [97].
As has been observed for their parent drugs, the different
forms of a chiral metabolite can differ in how they interact with
proteins. One report compared the chiral forms of oxybutynin
and its metabolite, N-desethyloxybutynin, in their binding and
competition on HSA and AGP. The results showed that the affinity of oxybutynin enantiomers on AGP was much higher than on
HSA, and that the enantiomers of N-desethyloxybutynin and oxybutynin were all bound by the same site on AGP [33]. Another
study involving the phenytoin metabolites m-HPPH and p-HPPH
compared the dissociation rates of the chiral forms of these metabolites from an HPLC column containing immobilized HSA
[98]. Dissociation rate constants of 8.2–9.6 s−1 were obtained at
pH 7.4 and 37° C for the enantiomers of m-HPPH, while values of
3.2–4.1 s−1 were obtained for the enantiomers of p-HPPH. These
results were then used along with separate estimates of the association equilibrium constants to also compare the association rate
constants for these metabolites and their enantiomers [98].
5.3. Use of binding data to characterize protein interaction
sites for drug metabolites
A number of reports have used binding data for drugs, their metabolites and related analogs to learn about the binding sites of
these compounds on a protein. Binding and retention data that
have been acquired by HPAC have been used to examine the binding of several types of compounds with immobilized serum proteins. This approach has been used to examine the binding of warfarin and coumarin compounds to HSA [99–101], as well as the
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binding of l-tryptophan and various indole compounds to this
protein [102, 103, 104]. The same general method has been used
to compare the binding of several sulfonylurea drugs with HSA
and various preparations of glycated HSA [39, 105–110].
If a relatively large group of compounds is considered in a
binding study, the results can be used to create a quantitative
structure-retention (or reactivity) relationship (QSRR) to describe
the site at which these agents are binding to a protein [111–114].
For instance, binding studies based on HPLC or CE using serum
proteins can be used to mimic biological systems and to quickly
study how changes in the structure of an applied drug or analog will alter these interactions [115, 116]. This format has been
used to build models that describe the binding of HSA with benzodiazepines [117–119]. Such an approach has also been utilized
to examine the binding of AGP with beta-adrenolytic drugs, antihistamines, amino alcohols, cyclic vinca alkaloid analogs, and
quinazolone derivatives [116, 120–125].
6. Interactions of proteins with xenobiotics and related
metabolites
The term “xenobiotics” refers to chemicals that are produced synthetically and that are not normally found in biological organisms
[126]. Drugs represent one type of xenobiotic, but others include
environmental pollutants and food additives [126–128]. When
they enter the body, xenobiotics can be metabolized through various enzymatic processes. The resulting metabolites, in turn, can
sometimes interact with proteins and compete for endogenous
compounds for common binding agents [126, 129].
Several studies have examined the effects that xenobiotics and
their metabolites may have on hormone–protein binding [127,
130, 131]. For example, the effect of polybrominated diphenyl
ethers (PBDEs) on the binding of thyroid hormones to serum proteins has been examined [131]. It has been suggested in several
studies that environmental exposure to PBDEs can result in decreased thyroid hormone concentrations in serum, leading to possible neurotoxicity and behavioral effects [131–133]. This effect
may be linked to the fact that, when metabolized, PBDEs become
hydroxylated and produce a chemical structure similar to that of
T4 and its metabolites. It has been further found that PBDE metabolites are able to bind to T4-binding proteins in serum, which
could result in the displacement of thyroid hormones. One study
examined the binding of transthyretin and TBG with fourteen hydroxylated PBDE compounds through various methods. A fluorescence displacement assay indicated that hydroxylated PBDEs
could compete with T4 for binding sites on transthyretin, while
work with circular dichroism indicated that hydroxylated PBDEs
could bind to the same sites as T4 on TBG and transthyretin [131].
Binding and competition with T4 has also been noted for some
polychlorinated biphenyls (PCBs), dichlorodiphenyltrichloroethane (DDT), and related metabolites or compounds with respect to
human thyroid receptor, TBG, and transthyretin [130].
Another report examined the effects for a number of xenobiotics and their metabolites on the binding of 17β-estradiol to the
estrogen receptor and on the binding of 5α-dihydrotestosterone
to the androgen receptor, androgen-binding protein, and SHBG
[127]. Compounds that were tested included hexachlorocyclohexane, DDT, methoxychlor, pentachlorophenol, and nonylphenol. It
was found that some of these xenobiotics and metabolites could
cause a significant decrease in the binding of 5α-hydrotestosterone
or 17β-estradiol to their binding proteins. It was further found that
binding by these xenobiotic agents could be selective for the steroid
receptors and binding proteins that were tested [127].
Polyphenolic compounds are flavonoids that are often used
as dietary supplements [128]. Ultrafiltration and CE were used
to examine the binding of these compounds to the human se-
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rum proteins HSA and AGP. Although similar in structure, these
compounds did vary in their affinity toward HSA, with a high
level of binding being observed for those compounds with hydrophobic properties and a carbonyl at position C(4) in their
structure. It was further noted that these hydrophobic properties did not play a major role in the ability of polyphenolic compounds to bind with AGP [128].
7. Variations in protein structure and binding due to metabolic processes
Another way in which changes in metabolites may affect solute protein interactions is through changes that are created in the structure of the protein. In some cases, these changes may be a direct result of the modification of a protein by a metabolite (e.g., glycation,
as discussed in the next section) [39, 80, 93, 134]. In others, this
change may be a response to differences in a protein’s environment
that are created as the metabolic profile is altered (e.g., as might occur through oxidation) [135, 136]. This section will discuss both
types of effects using changes that have been observed in serum
transport proteins and binding agents as examples.
7.1. Human serum albumin
One protein that has been found to be altered by some metabolic
diseases is HSA. As has been indicated earlier, HSA is a serum protein that plays a fundamental role in the reversible binding and
transport of metabolites, drugs and various endogenous ligands,
such as fatty acids [65, 137]. HSA is normally found in blood at
concentrations ranging from 30–50 g/L and accounts for approximately 60% of the total serum protein content [65]. Binding to
HSA is known to greatly influence the pharmacokinetics and activity of many common drugs [49, 138–140]. In addition, HSA
can increase the solubility of lipophilic drugs, sequester toxins,
and act as an important antioxidant in plasma [49, 65].
Several past studies have noted that the chemical modification of HSA can alter its binding to drugs, hormones and other
solutes. For instance, the reaction of HSA with p-nitrophenyl acetate, which is thought to mainly modify Tyr-411 at Sudlow site II,
can change the binding of various solutes with this protein [141].
The modification of Trp-214 by o-nitrophenylsulphenyl chloride
has been demonstrated to change the stereoselectivity and binding affinity of Sudlow site I of HSA [142]. Similar work has been
presented that has examined the effects of modifying the lone
free cysteine group on HSA by reacting this protein with ethacrynic acid [143, 144].
Diabetes is a metabolic disease in which the structure of HSA
can be modified. This disease is actually a group of disorders that
are characterized by abnormally high levels of blood glucose (i.e.,
hyperglycemia) that result from insulin deficiency and/or insulin resistance [145]. Many of the long term complications of diabetes, such as heart disease and nerve damage, are associated with the
non-enzymatic glycation of proteins [145, 146]. Glycation starts
with the nucleophilic attack of a reducing sugar (e.g., glucose) onto
some of the primary amine groups on proteins to form a reversible
Schiff base (see Figure 5). This intermediate can then slowly rearrange to form a more stable Amadori product [145–147]. Oxidation
of the Amadori products or free sugars can also generate reactive
α-oxaloaldehydes that can react with both lysines and arginines on
proteins to form advanced glycation end-products (AGEs) [147].
In recent years, it has been found that glycation can affect the
binding of several endogenous and exogenous solutes with HSA.
For example, l-tryptophan is an essential amino acid [148] and
has been extensively used as a site-selective probe for Sudlow site
II of glycated HSA and normal HSA [105, 106–108, 149]. Recent
binding studies using glycated HSA with levels of modification
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Figure 5. Reactions involved in the early stages of glycation of a protein, using human serum albumin (HSA) as an example [145].

similar to those found in diabetes found an increase of 4.7–5.8fold in the affinity of l-tryptophan for this protein at 37 °C [106,
149]. Sulfonylurea drugs are a group of anti-diabetic drugs that
are used in the management of type 2 diabetes; these drugs are
also highly bound to serum proteins such as HSA. Binding studies
based on HPAC have found that glycation can affect the binding
strength of these drugs to HSA, with both the degree of glycation
and the specific type of drug influencing the size of the change
[39, 105–110].
As indicated in the last section, fatty acids are the major endogenous ligands of HSA and are also known to have many binding sites on this protein [75]. Reports that have examined the combined effect of glycation and the presence of various fatty acids on
the binding of sulfonylurea drugs to HSA have found that glycation
increases the overall affinity of these drugs to HSA, while the addition of increasing amounts of fatty acids causes a decrease in affinity [74, 76]. It has further been noted that glycation could produce
changes of at least 3–5-fold in the affinities of some fatty acids at
their sites of competition with sulfonylurea drugs when comparing
the binding of these solutes to normal HSA [76].
Methylglyoxal is a highly reactive metabolite of glucose that
has been implicated in several chronic diseases associated with diabetes [150, 151]. The elevated concentrations of methylglyoxal
in diabetes patients can also lead to protein modification and the
formation of AGEs through the reaction of methylglyoxal with arginine or lysine residues. A recent report using quantitative MS
and multiple reaction monitoring found that a major site for modification by methylglyoxal on HSA occurs at Arg-257, which is located in Sudlow site I. Molecular modeling conducted in the same
study indicated that a decrease in binding by warfarin may occur due to these modifications when comparing glycated HSA and
normal HSA [151].
7.2. Alpha1-acid glycoprotein
A second type of serum transport protein that can be affected by
metabolic diseases is AGP. AGP is an acute-phase protein that is responsible for binding and delivering numerous basic and neutral
drugs in the bloodstream [121]. The concentration of AGP in blood
can vary over a wide range and is affected by systemic tissue injury,
inflammation and infection. In addition, the glycosylation of AGP
can be altered in some disease states, such as rheumatoid arthritis, systemic lupus erythematosus and autoimmune thyroid disease
[152]. These changes are important because they can also alter the
binding of drugs to AGP. As an example, the affinity of disopyramide for AGP has been found to be affected by the biantennary glycan structures for this protein [153, 154]. It has also been reported
that genetic variants of AGP can have a significant effect on binding
by chiral drugs such as disopyramide and warfarin [153, 155].

A number of reports have looked at how changes in AGP
binding can affect parent drugs compared to their metabolites.
One study evaluated the effect of AGP on lidocaine and its active metabolites monoethylglycinexylidide and glycinexylidide
during continuous epidural anesthesia in infants and young children. The results indicated the AGP concentration in plasma
could be used as an index to monitor and prevent the toxicity
caused by the accumulation of monoethylglycinexylidide during
the continuous administration of lidocaine [156]. Another report looked at the concentrations of vecuronium and its metabolite 3-OH desacetylvecuronium in children who were receiving
phenytoin or carbamazepine for chronic anticonvulsant therapy
[157]. These last two drugs were of interest because many anticonvulsant drugs have been shown to increase the concentration of AGP in plasma, which can then increase protein binding
to cationic drugs and alter their distribution. It was found that
the increase in AGP concentration associated with the anticonvulsant therapy did not significantly contribute to resistance to
vecuronium [158].
7.3. Lipoproteins
Lipoproteins are another set of binding agents in serum that can
be affected by metabolic diseases. Lipoproteins are macromolecular complexes of proteins and lipids that transport hydrophobic lipids and related compounds, such as cholesterol and triglycerides, throughout the body [158–161]. Lipoproteins are also
known to interact with several basic and neutral hydrophobic
drugs in blood [99, 162–172]. Examples of drugs that bind to lipoproteins are propranolol and verapamil [37, 162–175].
Lipoprotein concentrations in blood can vary with different
disease states. For example, the levels of low-density lipoprotein
(LDL) in plasma can increase in diseases such as atherosclerosis
and hyperlipidemia [176]. In addition to changes in the levels of
lipoproteins in the circulation, metabolic diseases often result in
modifications in lipoprotein structures. For instance, increased
amounts of LDL that have been modified by AGEs are found in
individuals with diabetics and non-diabetics with renal failure.
Glycation of LDL may lead to the formation of foam cells and an
increase in atherosclerosis. In addition, glycated LDL is more susceptible to further modifications due to oxidation [135].
The oxidation of lipoproteins occurs through free radicals, such
as peroxyl radicals, which are released from cells and chemical reactions [136]. These radicals can react with lipoproteins, depleting
the particle’s antioxidant defense and initiating oxidation of the
lipid core. In the later stages of this process, the surface protein
also becomes modified. The oxidation of lipoproteins, specifically
LDL, leads to atherosclerosis [136]. In addition to the increased
risk of atherosclerosis, oxidized lipoproteins may also impact the
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ability of the complexes to bind and carry basic and neutral drugs
throughout the body [176].
The effects of LDL oxidation on drug binding have been evaluated by using CE and using verapamil and nilvadipine as models
for basic and neutral drugs, respectively [176]. It was found that
the affinity of these drugs increased with the amount of LDL oxidation. In addition, the binding of verapamil was increased more
than it was for nilvadipine, suggesting that basic drugs were more
sensitive to oxidation effects. No stereoselective binding was detected between LDL and these model drugs at any oxidation state
[176]. However, other studies based on HPAC have noted different binding for the chiral forms of some drugs to LDL [174, 175].
8. Conclusion
The field of metabolomics has seen great growth in recent years because of the wealth of information it can provide about biochemical pathways and processes. This review examined previous reports
that have looked at the interactions of metabolites with proteins.
The first topic discussed was an overview of techniques that have
been used to characterize and study metabolite–protein binding.
These methods have been used in vitro and in vivo to provide information on the structures of metabolite–protein complexes and to
examine the nature of metabolite–protein interactions. Computational studies using in silico tools have been used to provide additional data on metabolite–protein complexes and interactions.
This review next described numerous studies that have investigated the binding of various types of small solutes and their metabolites with proteins. This included work that has been carried
out with hormones, fatty acids, drugs or other xenobiotics, and
their metabolites with transport proteins and receptors. These
examples have considered the structures of the resulting solute–
protein complexes, the nature of the binding sites, the strength of
these interactions, the variations in these interactions with solute
structure, and the kinetics of these reactions. Studies that have
examined the effects of various metabolic processes on the structure and activities of proteins, and on the corresponding interactions of solutes with these proteins, were also summarized.
Although most past work in metabolomics has been concerned
with the structure and analysis of metabolites, research in metabolite–protein interactions is still a relatively new area. Based on
the research that has already been carried out, it is already clear
that data on metabolite–protein interactions can provide useful
information on biological processes that involve hormones, drugs
and other low mass solutes. It is further expected that this type
of research will continue to grow in the future as metabolomics
becomes more widely used in biomedical research, pharmaceutical
science, and personalized medicine.
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